<DOC>
	<DOCNO>NCT00006021</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Vitamin C may increase effectiveness arsenic trioxide make cancer cell sensitive drug . PURPOSE : Phase I/II trial determine effectiveness arsenic trioxide plus vitamin C treat patient recurrent refractory multiple myeloma .</brief_summary>
	<brief_title>Arsenic Trioxide Plus Vitamin C Treating Patients With Recurrent Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose arsenic trioxide administer ascorbic acid patient recurrent refractory multiple myeloma . - Determine therapeutic efficacy treatment combination patient . - Determine expression MDR Bcl-xL gene intracellular level GSH patient treatment regimen ass whether measure prognostic value . OUTLINE : This multicenter , dose-escalation study arsenic trioxide . - Phase I : Patients receive arsenic trioxide IV 1-4 hour ascorbic acid IV 5-10 minute day 1-5 weekly 5 week . Treatment continue every 7 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) reach . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive MTD arsenic trioxide ascorbic acid outline . Patients follow monthly 5 year . PROJECTED ACCRUAL : A total 31-43 patient ( 6-18 phase I 16-25 phase II ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Mprotein serum protein electrophoresis urine protein electrophoresis Quantitative determination immunoglobulin Bone marrow biopsy aspirate plasma cell count great 10 % Refractory chemoresistant disease define failure respond ( le 50 % reduction M protein level ) progression within 2 month receive least 2 chemotherapy regimen include : Alkylating base regimen ( melphalan ) combination steroid ( prednisone ) chemotherapy regimen ( e.g. , vincristine , bleomycin , melphalan , cyclophosphamide , prednisone vincristine , carmustine , doxorubicin , prednisone ) Vincristine , doxorubicin , dexamethasone ( VAD ) regimen Pulse therapy high dose steroid alone High dose alkylating agent autologous stem cell transplantation Allogeneic bone marrow transplantation Plateau phase define M protein serum urine 6 week despite response prior therapy Must receive least 2 chemotherapy regimen list equivalent regimen Recurrent disease define progression 2 month initial therapy failure respond ( le 50 % reduction progression M protein level ) 1 chemotherapy regimen list salvage regimen ( e.g. , highdose cyclophosphamide topotecan ) Must receive VAD equivalent chemotherapy regimen Should consider autologous allogenic transplantation Prior local radiotherapy allow PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3* Platelet count least 50,000/mm^3* NOTE : *Unless attributable bone marrow infiltration multiple myeloma Hepatic : Bilirubin le 3 mg/dL Transaminases le 2.5 time upper limit normal ( ULN ) Renal : Creatinine le 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No cardiac arrhythmia include recurrent supraventricular arrhythmia , type sustain ventricular arrhythmia , conduction block ( atrioventricular block grade II III , leave bundle branch block ) Ejection fraction least 30 % No uncontrolled ischemic heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 4 month study HIV negative No grade 3 high neurological disorder , include seizure disorder No underlie medical condition would preclude study No active malignancy except adequately treat basal squamous cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 2 week since prior chemotherapy Endocrine therapy : See Disease Characteristics Concurrent steroid treatment allow except primary treatment myeloma Radiotherapy : See Disease Characteristics Concurrent local radiotherapy pain symptom control allow provide pain symptom related disease progression Surgery : Not specify Other : No concurrent ascorbic acid supplement No concurrent investigational drug therapy Concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>